In our previous studies on the treatment of melanoma cells with mTOR inhibitors, we have found that both rapamycin and everolimus had a significant impact on cell cycle regulation, cell proliferation (Ciołczyk-Wierzbicka et al. 2018), and invasive potential (Ciołczyk-Wierzbicka and Laidler 2018; Ciołczyk-Wierzbicka et al. 2020). This evidence concerns the gene MTOR and melanoma.